(CPS)" "R12.5: All patients taking GLP-1 agonists should be considered as at risk of having a full stomach despite a lack of gastrointestinal symptoms
The FDA-approved prescribing information for these medications lists gastrointestinal adverse effectsincluding nausea, vomiting, diarrhea, and in some cases eructation (belching)as common side effects
Meanwhile, the beauty industry is positioning products as a way to combat the hollowed look known as Ozempic face. Swiss pharmaceutical company Galderma, Cetaphils parent company, says it has seen growth from its injectables products that compete with Botox
However, certain symptoms are not normal and require immediate medical attention
Improved mitochondrial activity leads to better fat oxidation, more efficient energy use, and overall improved metabolic health
Conversely, relaxation techniques and distraction methods can substantially reduce awareness of the injection